BLUE / bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review

Bluebird bio said on Monday it has agreed to sell its priority review voucher for $103 million, if it gets the U.S. Food and Drug Administration's app more_horizontal

Are you looking for the best penny stocks to buy now? Today might be your day more_horizontal

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and pl more_horizontal

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebir more_horizontal

Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launchi more_horizontal

Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another app more_horizontal

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are w more_horizontal

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory com more_horizontal